Migraine Disorders
FDA clears its first prescription migraine app, from Click Therapeutics
United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first
FDA Approves Axsome’s Symbravo for Rapid Migraine Relief
Symbravo, meloxicam, rizatriptan, FDA approval, acute migraine treatment, rapid-acting, Axsome Therapeutics
FDA Approves Axsome’s Symbravo for Acute Migraine Treatment, Overcoming 2022 Rejection
Symbravo, Axsome Therapeutics, FDA approval, acute migraine treatment, meloxicam, rizatriptan, MoSEIC technology
Pfizer Agrees to $60 Million Settlement Over Nurtec Anti-Kickback Allegations
Pfizer, Nurtec, anti-kickback suit, settlement, Biohaven, migraine medicine
FDA Criticizes AbbVie for Misleading Ad Featuring Serena Williams Promoting Migraine Drug Ubrelvy
FDA, AbbVie, Serena Williams, Ubrelvy, Migraine Drug, Misleading Advertising
Pfizer Unveils PfizerForAll, a Direct-to-Consumer Platform for Migraine, Flu, and COVID-19 Products
PfizerForAll, Direct-to-Consumer, Migraine, Flu, COVID-19, Telehealth, Prescription Services, Vaccination Scheduling, Savings Programs
Pfizer Launches PfizerForAll: A Digital Platform to Simplify Healthcare Access
PfizerForAll, digital healthcare platform, telehealth, COVID-19, flu, migraines, healthcare access, patient support services